Lapatinib Moves Forward in Inflammatory and Early HER2-Positive Breast Cancer Trials
- 6 March 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 99 (5) , 348-349
- https://doi.org/10.1093/jnci/djk122
Abstract
Following on the heels of trastuzumab's success in HER2-positive breast cancer, lapatinib is moving rapidly through clinical development and already heading into trials in early breast cancer patients.Keywords
This publication has 0 references indexed in Scilit: